CURRICULUM VITAE
`
`Ian R. Judson MA, MD, FRCP
`
`June 2015
`
`1
`
`JANSSEN EXHIBIT 2029
`Mylan v. Janssen IPR2016-01332
`
`

`

`CONTENTS
`
`Personal details .................................................................................................................... 3
`
`Qualifications ........................................................................................................................ 3
`
`Present Appointment ............................................................................................................ 4
`
`Previous Appointments......................................................................................................... 4
`
`Publications
`
`-
`
`-
`
`-
`
`-
`
`-
`
`Peer review papers- ............................................................... 5
`
`Published abstracts-.............................................................22
`
`Books and book chapters.....................................................40
`
`Book reviews ........................................................................41
`
`Editorials...............................................................................41
`
`--
`
`Reviews and case reports ....................................................42
`
`-
`
`-
`
`-
`
`-
`
`Letters...................................................................................45
`
`MD Thesis ............................................................................45
`
`Patents .................................................................................45
`
`In press.................................................................................45
`
`Peer review and editorial activities
`-
`Journals & Grants................................................................46
`
`Principal Research Grants..................................................................................................47
`
`Invited Lectures: International.............................................................................................49
`
`Invited Lectures: National ...................................................................................................54
`
`Oral Proffered Papers.........................................................................................................58
`
`Conference Organisation ...................................................................................................59
`
`Invitations to Chair Meetings...............................................................................................59
`
`Teaching and Research Supervision..................................................................................62
`
`Membership of Committees and Cooperative Groups........................................................64
`
`Membership of Professional Bodies and Societies.............................................................64
`2
`
`

`

`3
`
`

`

`Name:
`
`Present Address:
`
`Ian Robert Judson
`
`2 Eastmearn Road
`London SE21 8HA
`
`Tel: 020 8761 6498
`E-mail:ian.judson@icr.ac.uk
`
`Date of Birth:
`
`23rd March 1951
`
`Marital Status:
`
`Married - three children
`
`Education:
`
`Bromsgrove High School
`Jesus College, Cambridge
`King's College, London
`
`Medical School:
`
`King's College Hospital Medical School
`
`GMC Registration No:
`
`2313692
`
`Medical Defence Union No: 125749H
`
`Qualifications:
`
`1972
`
`1973
`
`1976
`
`1978 (Feb)
`
`1978 (Oct)
`
`1988
`
`1989
`
`1991
`
`1994
`
`1996
`
`2001
`
`BA Natural Sciences
`(Upper 2nd Class Honours
`Part II Biochemistry)
`
`Cambridge University
`
`2nd MB
`
`MB BChir
`
`MRCP (Part I)
`
`MRCP (Part II)
`
`MD
`
`Cambridge University
`
`Cambridge University
`
`Royal College of Physicians
`
`RCP (London)
`
`Cambridge University
`
`Accreditation in Medical Oncology
`
`Recognised Teacher
`
`FRCP
`
`Faculty of Medicine,
`University of London
`
`RCP (London)
`
`Reader in Clinical Pharmacology
`
`University of London
`
`Professor of Cancer Pharmacology University of London
`
`4
`
`

`

`Present Appointment:
`Consultant
`Research
`
`Professor of Cancer Pharmacology/Honorary
`Medical Oncologist, The Institute of Cancer
`and Royal Marsden NHS Trust
`
`Previous Appointments
`
`1980-81
`
`Jan 80-Dec 80
`Medicine, St.
`
`Jan 81-June 81
`
`Royal
`
`Jul 81-Sept 81
`
`1981-83
`
`Oct 81-Sept 82
`
`Oct 82-Sept 83
`Hospital,
`Matthias)
`
`Nov 83-Apr 86
`Cancer
`
`Apr 86-Dec 86
`Dr. A.H.
`
`Rotational Post, Medicine SHO/Registrar
`
`SHO
`
`Intensive Therapy Unit and General
`George's Hospital
`
`SHO Medical Oncology Leukaemia Unit and Paediatric
`Oncology (Dr. R.L. Powles, Prof. T.J. McElwain),
`Marsden Hospital, Sutton
`
`Registrar General Medicine, St. George's Hospital
`
`Rotational Post, Medical Registrar
`
`Registrar in Cardiology, St. George's Hospital
`
`Registrar in Medical Oncology, Royal Marsden
`Fulham Road (Dr. E. Wiltshaw, Dr. J.
`
`Clinical Fellow & Hon. Senior Registrar Institute of
`Research and Royal Marsden Hospital
`
`Locum Consultant in Clinical Pharmacology (for
`Calvert)
`
`Jan 1987-Sep 1989
`of
`
`Lecturer in Medicine and Hon. Senior Registrar, Institute
`Cancer Research and Royal Marsden Hospital
`
`Jan 87-Dec 87
`
`Jan 88-Aug 88
`
`Sep 88-Sep 89
`M.E.Gore)
`
`Breast Unit (Dr. T.J. Powles)
`
`Lung Unit (Dr. I.E. Smith)
`
`Academic Medical Unit (Prof. T.J. McElwain, Dr.
`
`5
`
`

`

`PUBLICATIONS
`
`Peer reviewed research papers
`
`1.
`
`Watson J.G., Jameson B., Powles R.L., McElwain T.J., Lawson D.N.
`Judson I.R., Morgenstern G.R., Lumley H. And Kay H.E.M. Co- trimoxazole
`versus non-absorbable antibiotics in acute leukaemia. Lancet 1982;(i):6-9
`
`1. Judson I.R., Wiltshaw E. Cis-dichlorodiammineplatinum (cis- platinum) and
`Etoposide (VP-16) in malignant lymphoma - an effective salvage regimen.
`Cancer Chemother Pharmacol 1985;14:258-261
`
`2. Judson I.R., Wiltshaw E. Multiple myeloma in a pair of monozygotic twins, the
`first reported case. Brit J Haematol 1985;60:551-554
`
`3. Judson I.R., Wiltshaw E. A near death experience. Lancet 1983;(ii):561-562
`(reprinted as 'Aux Frontieres de la Mort', Journal International de la Medecine
`1984;8:307-311)
`
`4. Selby P., Kohn J., Raymond J., Judson I.R., McElwain T.J. Nephrotic
`syndrome following interferon therapy. Br Med J 1985;290:1180
`
`5. Rutty C.J., Judson I.R., Abel G., Goddard P.M., Newell D.R., Harrap K.R.
`formulation of N2,N4,N6–
`Preclinical
`toxicology, pharmacokinetics and
`trihydroxymethyl -N2,N4,N6-
`trimethylmelamine (Trimelamol), a water-soluble
`cytotoxic s- triazine which does not require metabolic activation. Cancer
`Chemother Pharmaco. 1986;17:251-258
`
`6. Judson I.R., Rutty C.J., Abel G., Graham M.A. Low central nervous system
`N2,N4,N6-trihydroxymethyl-N2,N4,N6-
`penetration
`of
`trimethylmelamine
`(Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. Br J Cancer
`1986;53:601-606
`
`7. Calvert A.H., Newell D.R., Jackman A.L., Gumbrell L.A., Sikora E.,
`Grzelakowska-Sztabert B., Bishop J.A.M., Judson I.R., Harland S.J., Harrap
`K.R. Recent preclinical and clinical studies with the thymidylate synthase
`inhibitor N10-propargyl-5,8-dideazafolic acid
`(CB 3717).
` NCI Monogr
`1987;5:213-218
`
`8. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E.,
`Siddik Z.H., Judson I.R., Gore M.E., Wiltshaw E. Carboplatin dosage:
`Prospective evaluation of a simple formula based on renal function. J Clin
`Oncol 1989;11:1748-1756
`
`6
`
`

`

`9. Judson I.R., Calvert A.H., Rutty C.J., Abel A., Gumbrell L.A., Graham M.A.,
`Evans B.D., Wilman D.E.V., Ashley S.E., Cairnduff F. Phase I trial and
`(N2,N4,N6-trihydroxymethyl-N2,N4,N6-
`pharmacokinetics
`of
`Trimelamol
`trimethylmelamine) Cancer Res 1989;49:5475-5479
`
`10. Gore M.E., Viner C., Meldrum M., Bell J., Milan S., Zuiable A., Slevin M., Selby
`P.J., Clark P.I., Millar B., Maitland J.A., Judson I.R., Tillyer C. & McElwain T.J.
`Intensive treatment of multiple myeloma and criteria for complete remission.
`Lancet 1989;(ii): 879-881.
`
`11. McElwain T.J., Gore M.E., Meldrum M., Viner C., Judson I.R., Malpas J.S.
`VAMP followed by high dose melphalan and autologous bone marrow
`transplantation for multiple myeloma. Bone Marrow Transplant 1989;4, Suppl
`4:109-112
`
`12. Hardy J.R., Powles T.J., Judson I.R., Heron C., Williams M., Cherryman G.,
`Husband J., Cosgrove D., Blaszczyk M., Sinnett H.D., Ashley S.E., Trott P.A.
`How many tests are required in the diagnosis of palpable breast abnormalities?
`Clin Oncol 1990;2:148-152.
`
`13. Hardy J.R., Powles T.J., Judson I.R., Sinnett H.D., Ashley S.E., Coombes R.C.,
`Ellin C.L.
` Combination of
`tamoxifen, aminoglutethimide, danazol and
`medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer
`1990;36:824-827.
`
`14. Hardy J., Smith I., Cherryman G., Vincent M., Judson I., Perren T., Williams M.
`The value of computed tomographic (CT) scan surveillance in the detection and
`management of brain metastases in patients with small cell lung cancer. Br J
`Cancer 1990;62:684-686.
`
`15. Judson I.R., Calvert A.H., Gore M.E., Gumbrell L.A., Perren T, Wiltshaw E.
`Phase II trial of Trimelamol in refractory ovarian cancer. Br J Cancer
`1991;63:311-313.
`
`16. Powles T.J., Jones A.L., Judson I.R., Hardy J.R., Sinnett H.D., Ashley S.E.
`Low toxicity combination cytotoxic chemotherapy of advanced breast cancer
`using mitomycin C, mitozantrone and methotrexate (3M) or vincristine,
`anthracycline and cyclophosphamide (VAC). Br J Cancer 1991;64:406-410.
`
`17. Jackman A.L., Taylor G.A., Gibson W., Kimbell R., Brown M., Calvert A.H.,
`Judson I.R., Hughes L.R. ICI D1694, a quinazoline antifolate thymidylate
`synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro
`and in vivo; A new agent for clinical study. Cancer Res 1991;51:5579-5586.
`
`18. Talbot D.C., Smith I.E., Mansi J.L., Judson I.R., Calvert A.H., Ashley S.E.
`Anthrapyrazole CI941: A Highly Active New Agent in the Treatment of
`Advanced Breast Cancer. J Clin Oncol 1991;9:2141-2147.
`
`7
`
`

`

`19. Kaye S.B., Wanders J., Clavel M., Verweij J., Piccart M., Smyth J.F., Ten
`Bokkel Huinink W.W., Wagener D.J.T., Judson I.R., & Cavalli F. Phase II trials
`of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary
`and melanoma. Ann Oncol 1992;5:406-408.
`
`20. Mansi J., Da Costa F., Viner C., Judson I., Gore M., Cunningham D. High-dose
`busulfan in patients with myeloma. J Clin Oncol 1992;10:1569-1573.
`
`21. Hickish T., Serafinowski P., Cunningham D., Oza A., Dorland E., Judson I.,
`Millar B.C., Lister T.A., Roldan A. 2'-Chlorodeoxyadenosine: evaluation of a
`novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J
`Cancer 1993;67:139-143.
`
`22. Gibson W., Bisset G.M.F., Marsham P.R., Kelland L.R., Judson I.R., Jackman
`A.L. The measurement of polyglutamate metabolites of the thymidylate
`synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem
`Pharmacol 1993;45:863-869.
`
`23. Jodrell D.I., Gibson W., Bisset G.M.F., Boyle F.T., Judson I.R., Jackman A.L.
`The in vivo metabolic stability of dipeptide analogues of the quinazoline
`antifolate ICI 198583, in mice. Biochem Pharmacol 1993;46:2229-2234.
`
`24. Jarman M., Coley H.M., Judson I.R., Thornton T.J., Wilman D.E.V., Abel G.,
`Rutty C.J. Synthesis and cytotoxicity of potential tumour-inhibitory analogues
`of Trimelamol (2,4,6-Tris[(hydroxymethyl)(methyl)amino]-1,3,5-triazine) having
`electron-withdrawing groups in place of methyl. J Med Chem 1993;36:4195-
`4200.
`
`liquid
` High performance
`I.R.
`25. Raynaud F., Walton M. And Judson
`chromatographic assay for the measurement of the novel microtubule inhibitor
`1069C85 in biological tissues and fluids. J Chromatog 1993;622:243-248.
`
`26. Clarke S.J., Jackman A.L., Judson I.R. The toxicity of ICI D1694 in man and
`mouse. Adv Ex Med Biol 1993;338:601-604.
`
`27. Catimel G., Vermorken J.B., Clavel M., De Mulder P., Judson I., Sessa C.,
`Piccart M., Bruntsch U., Verweij J., Wanders J., Franklin H., Kaye S.B. A
`Phase II study of Gemcitabine (LY 188011) in patients with advanced
`squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:543-547.
`
`28. Verweij J., Judson I., Steward W., Coleman R., Woll P., Van Pottelsberghe C.,
`Van Glabbeke M., Mouridsen H. Phase II study of liposomal muramyl tripeptide
`phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the
`adult. An EORTC Soft Tissue and Bone Sarcoma Group study. Eur J Cancer
`1994;30A:842-843.
`
`29. Bleehan N.M., Calvert A.H., Lee S.M., Harper P., Kaye S.B., Judson I.R.,
`Brampton M. A Cancer Research Campaign (CRC) phase II trial of CB10-277
`
`8
`
`

`

`given by 24 hour infusion for malignant melanoma. Br . Cancer 1994;70:775-
`777.
`
`30. Raynaud F., Kelland L.R., Walton M.I., Judson I.R. Preclinical pharmacology of
`1069C85, a novel tubulin binder. Cancer Chemother Pharmacol 1994;35:169-
`173.
`
`31. Coley H.M., Jarman M., Brooks N., Thornton T.J., Judson I.R. (1994): Stable
`analogues of the antitumour agent Trimelamol retain in vitro cytotoxicity in drug-
`sensitive and resistant rodent and human cell
`lines.
` Eur J Cancer
`1994;30A(12):1827-1835.
`
`32. Coley H.M., Brooks N., Phillips D., Hewer A., Jenkins T., Jarman M., Judson
`I.R. The role of the N-(hydroxymethyl) melamines as antitumour agents:
`Mechanism of action studies. Biochem Pharmacol 1995;49:1203-1212.
`
`33. Coombes R.C., Haynes B.P., Dowsett M., Quigley M., English J., Judson I.R.,
`Griggs L.J., Potter G.A., McCague R., Jarman M. Idoxifene: Report of a phase
`I study in patients with metastatic breast cancer. Cancer Res 1995;55:1070-
`1074.
`
`34. Cowie F., Pinkerton C.R., Philips M., Dick G., Judson I., McCarthy P.T.,
`Flanagan R.J. Continous-infusion verapamil with etoposide in relapsed or
`resistant paediatric cancers. Br J Cancer 1995;71:877-881.
`
`35. McKeage M.J., Mistry P., Ward J., Boxall F.E., Loh S., O'Neill C., Ellis P.,
`Kelland L.R., Morgan S.E., Murrer B.A., Santabarbara P., Harrap K.R., Judson
`I.R. A phase I and pharmacological study of an oral platinum complex (JM216):
`Dose-dependent pharmacokinetics with single dose administration. Cancer
`Chemother Pharmacol 1995;36:451-458.
`
`36. Coley H.M., Brooks N., Phillips D., Hewer A., Jenkins T., Jarman M. & Judson
`I.R. The role of the N-(hydroxymethyl)melamines as antitumour agents:
`mechanism of action studies. Biochem Pharmacol1995;49:1203-1212.
`
`37. Pintao A.M., Paid M.S.S., Coley H., Kelland L.R., Judson I.R. In vitro and in
`vivo antitumor activity of benzyl
`isothiocyanate: A natural product from
`Tropaeolum majus. Planta Med. 1995;61:233-236.
`
`38. Artemov D., Bhujwalla Z.M., Maxwell R.J., Griffiths J.R., Judson I.R., Leach
`M.O., Glickson J.D. Pharmacokinetics of the 13C labelled anticancer drug
`temozolomide detected in vivo by selective cross polarization transfer. Mag
`Res Med 1995;34:338-342.
`
`39. Van Geel A.N., Pastorino U., Jauch K.W., Judson I.R., Van Coervorden F.,
`Buesa J.M., Nielsen O.S., Boudinet A., Tursz T., Schmitz P.I. Surgical
`Treatment of Lung Metastases: the EORTC-STBSG study of 255 patients.
`Cancer 1996:77:657-682.
`
`9
`
`

`

`40. Clarke S.J., Hanwell J., de Boer M., Planting A., Verweij J., Walker M., Smith
`R., Jackman A.L., Hughes L.R., Harrap K.R., Kennealey G.T., Judson I.R.
`Phase I Trial of ZD1694, a New Folate-Based Thymidylate Synthase Inhibitor in
`Patients with Solid Tumours. J Clin Oncol 1996;14(5):1495-1503.
`
`41. Koh J-I., Kbota T., Hoshiya Y., Asanuma F., Yamada Y., Kitajima M., Coley
`H.M., Judson I.R. Antitumour effect of trimelamol against human breast
`carcinoma xenografts in nude mice. Oncol Rep 1996;3:613-617.
`
`42. Coley H.M., Jarman M, Jones M., Sargent J.M., Kubota T., Lee N.C.J., Goddard
`P.M., Elgie A.W., Williamson C, Taylor C.G., Judson I.R. The activity of N-
`(hydroxymethyl)melamines in fresh human ovarian tumour cells and xenografts.
`Anticancer Res 1996;16:1851-1856.
`
`43. Coley H.M., Jarman M, Brooks N, Kubota T, Goddard P.M., Jones M, Lee N,
`Owens M.D., Halbert G.W. and Judson I.R. Preclinical development of the
`antitumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable
`analogue of trimelamol. Int J Cancer 1996;68:356-363.
`
`44. Judson I. Briasoulis E., Raynaud F., Hanwell J., Berry C., Lacey H. Phase I trial
`and pharmacokinetics of the tubulin inhibitor 1069C85 - a synthetic agent
`binding at the colchine site designed to overcome multidrug resistance. Br J
`Cancer 1996;75(4):608-613.
`
`45. Orr R.M., Raynaud F.I., Goddard P.M., Judson I.R., Beck T., Bryan B., Cotter F.
` Pharmacologic disposition of a phosphorothioate oligodeoxynucleotide in
`mice. Nucleosides & Nucleotides 1997;16(6-9):1699-1702.
`
`46. Lebedev A.V., Raynaud F., Dizik M., Beck T., Jaeger J.A. Brown B.D.,
`Cunningham D., Webb A., McCampbell E., Riley T., Judson I., Woodle M.C.
`Anti-BCL2 phosphorothioate G3139 clinical pharmacology: Plasma levels
`during continuous subcutaneous infusion by HPLC assay. Nucleosides &
`Nucleotides 1997;16(6-9):1699-1702.
`
`47. Verrill M.W., Judson I.R. Harmer C.L., Fisher C., Thomas J.M., Wiltshaw E.
`"Ewing's sarcoma and primitive neuroectodermal tumour (PNET) in adults: Are
`they different from Ewing's sarcoma and PNET in children?" J Clin Oncol
`1997;15(7):2611-2621.
`
`48. McKeage M.J., Raynaud F., Ward J., Berry C., Odell D., Kelland L.R., Murrer B.,
`Santabarbara P., Harrap K.R., Judson I.R. A phase I and pharmacokinetic
`study of an oral platinum complex (JM216) given daily for five days. J Clin
`Oncol 1997;15(7):2691-2700.
`
`49. Judson I.., Cerny T., Epelbaum R., Dunlop D., Smyth J., Schaefer B., Roelvink
`M., Kaplan S., Hanauske A. Phase II trial of the oral platinum complex JM216 in
`non-small cell
`lung cancer: An EORTC Early Clinical Studies Group
`investigation. Ann Oncol 1997;8:604-608.
`
`10
`
`

`

`50. Raynaud F.I., Orr R.M., Goddard P.M., Lacey H., Lancashire H., Judson I.R.,
`Beck T., Bryan B., Cotter F.E. Pharmacokinetics of G3139, a phosphorothioate
`oligodeoxynucleotide antisense to bcl-2, after intravenous administration or
`continuous subcutaneous
`infusion
`to mice.
` J Pharmacol Exp Ther
`1997;281:420-427.
`
`51. Verrill M.W., Judson I.R., Wiltshaw E., Thomas J.M., Harmer C.L., Fisher C.
`The use of paediatric chemotherapy protocols at full dose is both a rational and
`feasible treatment strategy in adults with Ewing’s family tumours. Ann Oncol
`1997;8:1099-1105.
`
`52. McSheehy, P.M.J., Seymour M.T., Ojugo A.S.E., Rodrigues L.M., Leach M.O.,
`Judson I.R., Griffiths J.R. A pharmacokinetic and pharmacodynamic study of in
`vivo human HT29 tumours 19F and 31P magnetic resonance spectroscopy. Eur
`J Cancer 1997;33(14):2427-2427.
`
`53. Gwyther S., Bolis G., Gore M., Huinink W.T., Verweij J., Judson I.R., Despax R.,
`Jimenez-Lacave A. Experience with independent radiological review during a
`topotecan trial in ovarian cancer. Ann Oncol 1997;8:463-468.
`
`54. Ojugo A.S.E., McSheehy P.M.J., Stubbs M., Alder G., Bashford C.L., Maxwell
`R.J., Leach M.O., Judson I.R., Griffiths J.R. Influence of pH on the uptake of 5-
`fluorouracil into isolated tumour cells. Br J Cancer 1998;77(6)873-879.
`
`55. Crawley C.R., Judson I.R., Verrill M., Hill C., Raynaud F. A phase I/II study of a
`72 hour continuous infusion of etoposide in advanced soft tissue sarcoma.
`Sarcoma 1998;1:149-154.
`
`56. McSheehy P.M.J., Robinson S.P., Ojugo A.S.E., Aboagye E.O., Cannell M.B.,
`Leach M.O., Judson I.R., Griffiths J R. Carbogen breathing increases 5-
`fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: A magnetic
`resonance study in vivo. Cancer Res 1998;58:1185-1194.
`
`57. Beale P., Judson I., Hanwell J., Berry C., Aherne W., Hickish T., Martin P.,
`Walker M. Metabolism, excretion and pharmacokinetics of a single dose of
`[14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 1998;42:71-
`76.
`
`58. Beale P., Raynaud F., Hanwell J., Berry C., Moore S., Odell D., Judson I. A
`phase I study of oral JM216 administered twice daily. Cancer Chemother
`Pharmacol 1998;42:142-148.
`
`59. Millar B.C., Millar J.L., Shepherd V., Blackwell P., Porter H., Cunningham D.,
`Judson I., Treleaven J., Powles R.L., Catovsky D. (1998). The importance of
`CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer
`patients given peripheral blood stem cell rescue. Bone Marrow Transplantation
`1998;22:469-475.
`
`11
`
`

`

`60. Judson I., Maughan T., Beale P., Primrose J., Hoskin P., Hanwell J., Berry C.,
`Walker M., Sutcliffe F.
` Effects of
`impaired
`renal
`function on
`the
`pharmacokinetics of raltritrexed (Tomudex TM
` ZD1694). Br J Cancer
`1998;78(9):1188-1193.
`
`61. Clarke S.J., Hanwell J., De Boer M., Planting A., Verweij J., Walker M., Smith
`R., Jackman A.L., Hughes L.R., Harrap K.R., Kennealey G.T., Judson I.R.
`Phase I Trial of ZD1694, a New Folate-Based Thymidylate Synthase Inhibitor in
`Patients with Solid Tumours. Classic Papers and Current Comments
`1999;4(1):88-90.
`
`62. Woll P.J., Judson I., Lee S.M., Rodenhuis S., Nielsen O.S.., Buesa J.M.,
`Lorigan P.C., Leyvraz S., Hermans C., Van Glebbeke M., Verweij J.
`Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II
`study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer
`1999;35(3):410-412.
`
`63. Twelves C.J., Gardner C., Flavin A., Sludden J., Dennis I., de Bono J., Beale
`P., Vasey P., Hutchison C., Macham M.A., Rodriguez A., Judson I., Bleehan
`N.M. for the CRC Phase I/II Committee Phase I and pharmacokinetic study of
`DACA (XR5000): a novel inhibitor of topoisomerase I and II. Br J Cancer
`1999;80(11):1786-1791.
`
`64. Verrill M.W., Coley H.M., Judson I.R., Fisher C. Susceptibility of fibromatosis
`cells in short-term culture to ifosfamide: a possible experimental treatment in
`clinical aggressive cases. Sarcoma 1999;3:79-84.
`
`65. Beale P., Judson I., Moore S., Statkevic P., Marco A., Cutler D.L., Reidenberg
`P., Brada M. Effect of gastric pH on the oral bioavailability of temozolomide.
`Cancer Chemother Pharmacol 1999;44:389-394.
`
`66. Judson I.R., Beale P.J., Trigo J.M., Aherne W., Crompton T., Jones D., Bush
`E., Reigner B. A human Capecitabine excretion balance and pharmacokinetic
`study after administration of a single oral dose of 14C-labelled drug. Inv. New
`Drugs 1999;17:49-56.
`
`67. Brada M., Judson I., Beale P., Moore S., Reidenberg P., Statkevich P., Dugan
`M., Batra V., Cutler D. Phase I dose-escalation and pharmacokinetic study of
`temozolomide
`(SCH 52365)
`in patients with
`refractory or
`relapsing
`malignancies. Br J Cancer 1999;81(6):1022-1030.
`
`68. Blay J-Y, Judson I., Rodenhuis S., Hermans C., Smith C., van Glabbeke M.,
`Verweij J. Phase II study of raltitrexed (‘Tomudex’) for patients with advanced
`soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer
`Drugs 1999;10(10):873-877.
`
`69. Ojugo A.S., McSheehey P.M., Mcintyre D.J., Mccoy C., Stubbs M.,, Leach M.O.,
`Judson I.R., Griffiths J.R. Measurement of the extracellular pH of solid tumours
`in mice by magnetic resonance spectroscopy: a comparison of exogenous
`(19)F and (31)P probes. NMR Biomed 1999;12(8):495-504
`
`12
`
`

`

`70. Nielsen O.S., Judson I., van Hoesel Q., le Cesne A., Keizer H.J., Blay J.Y., Van
`Oosterom A., Radford J.A., Svancarova L., Krzemienlecki K., Hermans C., Van
`Glabbeke M., Oosterhuis J.W., Verweij J. Effect of high-dose ifosfamide in
`advanced soft tissue sarcomas. A multicentre phase II study of the EORTC
`Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000;36:61-67.
`
`71. Coley H.M., Verrill M.W., Gregson S.E., Odell D.E., Fisher C., Judson I.R.
`Incidence of P-glycoprotein overexpression and multidrug resistance (MDR)
`reversal in adult soft tissue sarcoma. Eur J Cancer 2000;36:881-888.
`
`72. le Cesne A., Judson I., Crowther D., Rodenhuis S., Keizer H.J., van Hoesel Q.,
`Blay J-Y., Frisch J., van Glabbeke M., Hermans C., van Oosterom A., Tursz T.,
`Verweij J. Randomized phase
`III study comparing conventional-dose
`doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus
`recombinant human granulocyte-macrophage colony-stimulating
`factor
`in
`advanced soft tissue sarcomas: A trial of the European Organization for the
`Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J
`Clin Oncol 2000;18(14):2676-84.
`
`73. Verweij J., Lee S.M., Ruka W., Buesa J., Coleman R., Van Hoesel R.,
`Seynaeve C., Donato di Paola E., van Glabbeke M., Tonelli D., Judson I.R.
`Randomized phase II study of docetaxel versus doxorubicin in first- and
`second-line chemotherapy for locally advanced or metastatic soft tissue
`sarcomas in adults: A study of the European Organization for Research and
`Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol
`2000;18:2081-2086
`
`74. McSheehy P.M., Leach M.O., Judson I.R., Griffiths J.R. Metabolites of 2’-fluoro-
`2’deoxy-D-glucose detected by 19F magnetic resonance spectroscopy in vivo
`predict response of murine RIF-1 tumours to 5-fluorouracil. Cancer Res
`2000;60(8):2122-7.
`
`75. Clarke P.A., Hostein I., Banerji U., Stefano F.D., Maloney A., Walton M., Judson
`I., Workman P. Gene expression profiling of human colon cancer cells following
`inhibition signal transduction by 17-allylamino-17-demethoxygeldanamycin, an
`inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19(36):4125-4133.
`
`76. Gwyther S.J., Nielsen O.S., Judson I.R., van Glabbeke M., Verweij J.
`Radiologist review versus group peer review of claimed responses in a phase II
`study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A
`study of the EORTC Soft Tissue and Bone Sarcoma Group. Anticancer Drugs
`2000;11(6):433-7.
`
`77. Briasoulis E., Judson I., Pavlidis N., Beale P., Wanders J., Groot Y., Veerman
`G., Schuessler M., Niebch G., Siamopoulos K., Tzamakou E., Rammou D.,
`Wolf L., Walker R., Hanauske A. Phase I trial of 6-hour infusion of glufosfamide
`(D-19575) a new alkylating agent with potentially enhanced selectivity for
`tumors that overexpress transmembrane glucose transporters. A study of the
`European Organization for Research and Treatment of Cancer Early Clinical
`Studies Group. J Clin Oncol 2000;18(20):3535-44.
`
`13
`
`

`

`78. Spillane A.J., A’Hern R., Judson I.R., Fisher C., Thomas J.M. Synovial
`Sarcoma: A clinicopathological, staging and prognostic assessment. J Clin
`Oncol 2000;18(22):3794-803.
`
`79. Judson I., Radford J.A., Harris M., Blay J-Y., van Hoesel Q., le Cesne A., van
`Oosterom A.T., Clemons M.J., Kamby C., Hermans C., Whittaker J., Donato di
`Paola E., Verweij J., Nielsen O.S. Randomised phase II trial of pegylated
`liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment
`of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft
`Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877.
`
`80. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato Di Paola E.,
`Dimitrijevic S., Martens M., Webb A., Sciot R., van Glabbeke M., Silberman S.,
`Nielsen O.S; European Organisation for Research and Treatment of Cancer
`Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571)
`in metastatic gastrointestinal stromal tumours: a phase I study. Lancet
`2001;358:1421-23.
`
`81. Ng C., Stebbing J., Judson I. Cardiac metastasis from a myxoid liposarcoma.
`Clin Oncol 2001;13:384-385
`
`82. Fyfe D., Raynaud F., Langley R.E., Newell D.R., Halbert G., Gardner C., Clayton
`K., Woll P.J., Judson I., Carmichael J. A study of amsalog (CI-921)
`administered orally on a 5-day schedule, with bioavailability and
`pharmacokinetically guided dose escalation. Cancer Chemother Pharmacol
`2002;49(1):1-6
`
`83. Ford H.E., Mitchell F., Cunningham D., Farrugia D.C., Hill M.E., Rees C.,
`Calvert A.H., Judson I.R., Jackman A.L. Patterns of elevation of plasma 2’-
`deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after
`administration of two different schedules of 5-fluorouracil and the specific TS
`inhibitors Raltritrexed (Tomudex) and ZD9331. Clin Cancer Res 2002;8(1):103-
`9
`
`84. van Glabbeke M., Verweij J., Judson I., Nielsen O. on behalf of the EORTC Soft
`Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-
`point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549
`
`85. Svancarova L., Blay J.Y., Judson I.R., Van Hoesel Q.G., van Oosterom A., le
`Cesne A., Keizer H.J., Hermans C., van Glabbeke M., Verweij J., Hogendoorn
`P.C., Nielsen O.S. (2002). Gemcitabine in advanced adult soft-tissue
`sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma
`Group. Eur J Cancer 2002;38(4):556-559.
`
`86. Kumar P., Judson I., Nicholson A.G., Ladas G. Mediastinal Haemangioma:
`successful treatment by alpha-2a interferon and post-chemotherapy resection.
`J Thorac Cardiovasc Surg 2002;124:404-406.
`
`87. van Oosterom A.T., Mouridsen H.T., Nielsen O.S., Dombernowsky P.,
`Krzemienlecki K., Judson I., Svancarova L., Spooner D., Hermans C., van
`
`14
`
`

`

`Glabbeke M., Verweij J. for the EORTC STBSG. Results of randomized
`studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two
`different ifosfamide regimens in first and second line chemotherapy in
`advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-406
`
`88. van Oosterom A.T., Judson I.R., Verweij J., Stroobants S., Dumez H., Donato di
`Paola E., Sciot R., van Glabbeke M., Dimitrijevic S., Nielsen O.S.; European
`Organisation for Research and Treatment of Cancer Soft Tissue and Bone
`Sarcoma Group. Update of phase I study of imatinib (STI571) in advanced soft
`tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC
`Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38 Suppl 5:S83-7
`
`89. O'Donnell A, Punt C.J., Judson I., van Maanen L, Suttle A.B., Ertel P., Beale P.
`A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil
`after concurrent administration to patients with refractory solid tumours and
`varying degrees of renal impairment (FUMA1005). Cancer Chemother
`Pharmacol 2003;51(1):58-66
`
`90. Burkill G.J.C., Badran M., Al-Muderis O., Thomas J.M., Judson I.R., Fisher C.,
`Moskovic E.C. Malignant gastrointestinal stromal tumor: distribution, imaging
`features, and pattern of metastatic spread. Radiology 2003;226:527-532
`
`91. McSheehy P.M., Troy H., Kelland L.R., Judson I.R., Leach M.O., Griffiths JR.
`Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour
`growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J
`Cancer 2003;39:532-40
`
`92. Lee Y.F., John M., Edwards S., Clark J., Flohr P., Maillard K., Edema M., Baker
`L., Mangham D.C., Grimer R., Wooster R., Thomas J.M., Fisher C., Judson I.,
`Cooper C.S. Molecular classification of synovial sarcomas, leiomyosarcomas
`and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer
`2003;24;88:510-5
`
`93. Asad Y., Cropp G., Adams A., O'Donnell A., Raynaud F., Judson I., Workman
`P. Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-
`dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic
`acid (SU006668) in human plasma and its application to a phase I clinical trial.
`J Chromatogr B Analyt Technol Biomed Life Sci 2003;785:175-86
`
`95. Rees C, Beale P, Trigo JM, Mitchell F, Jackman A, Smith R, Douglass E,
`Judson I. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase
`inhibitor, given as a 5-day continuous infusion to patients with refractory solid
`malignancies. Clin Cancer Res 2003;9:2049-55
`
`96. Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A,
`Oosterhuis JW, Judson I, Nielsen OS. Advanced soft-tissue sarcoma: a
`disease that is potentially curable for a subset of patients treated with
`chemotherapy. Eur J Cancer 2003;39:64-9
`
`15
`
`

`

`97. Beale P., Judson I., O’Donnell A., Trigo J., Rees C., Raynaud F., Turner A.,
`Simmons L., Etterley L. A phase I clinical and pharmacological study of cis-
`diamminedichloro (2-methylpyridine) platinum II (AMD473). Br J Cancer
`2003;88(7):1128-34
`
`98. Plummer R., Rees C., Hughes A., Beale P., Highley M., Trigo J., Gokul S.,
`Judson I., Calvert H., Jackman A., Mitchell F., Smith R., Douglass E. A phase I
`trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase
`inhibitor. Clin Cancer Res 2003;9:1313-22.
`
`99. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W,
`Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS.
`Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for
`gastrointestinal stromal tumours, but does not yield responses in other soft-
`tissue sarcomas that are unselected for a molecular target. Results from an
`EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer
`2003;39(14):1976-7
`
`Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G, Barca R,
`100.
`Judson I, Lodge N, Meldolesi E, Simontacchi G, Piperno G, Galardi A